Jump up ^ Fernández-Ruiz J, Sagredo O, Pazos MR, García C, Pertwee R, Mechoulam R, Martínez-Orgado J (February 2013). "Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?". British Journal of Clinical Pharmacology. 75 (2): 323–33. doi:10.1111/j.1365-2125.2012.04341.x. PMC 3579248. PMID 22625422.
In the meantime, some physicians are forging ahead — and cashing in. Joe Cohen is a doctor at Holos Health, a medical marijuana clinic in Boulder. I asked him what CBD is good for, and he read me a long list of conditions: pain, inflammation, nausea, vomiting, intestinal cramping, anxiety, psychosis, muscle spasms, hyperactive immune systems, nervous system degeneration, elevated blood sugar and more. He also claimed that CBD has anti-cancer properties and can regenerate brain cells and reduce the brain’s levels of amyloid beta — a kind of protein that’s been linked to Alzheimer’s disease. I asked for references, noting that most of these weren’t listed in the Academies report or a similar review published in the Journal of the American Medical Association. “I think you just have to Google search it,” he said. It’s true that a preliminary study found hints that cannabinoids might reduce beta amyloid proteins in human brain cells, but the study was done in cells grown in a lab, not in people. As for cancer, the FDA sent warning letters last year to four companies that were selling products that claimed to “prevent, diagnose, treat or cure” cancer.
You cannot have a fatal overdose from cannabis use. However, if you have too much in one session it can lead to a very unpleasant experience. Anxiety and panic attacks, disorientation, and inability to focus are all signs you have had too much. Other negative effects from taking too much include loss of coordination, shortness of breath, increased heart rate and shaking, chills and sweats.
No ongoing clinical trials of Cannabis as a treatment for cancer in humans were identified in a PubMed search. The only published trial of any cannabinoid in patients with cancer is a small pilot study of intratumoral injection of delta-9-THC in patients with recurrent glioblastoma multiforme, which demonstrated no significant clinical benefit.[19,20] In a trial (NCT02255292) conducted in Israel, oral cannabidiol (CBD) was investigated as a single salvage agent for recurrent solid tumors. The study was projected to be completed in 2015; however, no results have been published. A small exploratory phase II study (GWCA1208 Part A [NCT01812603]) was conducted in the United Kingdom that used nabiximols, a 1:1 ratio of THC:CBD in a Cannabis-based medicinal extract oromucosal spray, in conjunction with temozolomide in treating patients with recurrent glioblastoma multiforme. The study enrolled 21 patients. Final results have not been published.
Hemp, grown under license mostly in Canada, is the most publicized “new” crop in North America. Until very recently the prohibition against drug forms of the plant prevented consideration of cultivation of fiber and oilseed cultivars in Canada. However, in the last 10 years three key developments occurred: (1) much-publicized recent advances in the legal cultivation of hemp in western Europe, especially for new value-added products; (2) enterprising farmers and farm groups became convinced of the agricultural potential of hemp in Canada, and obtained permits to conduct experimental cultivation; and (3) lobby groups convinced the government of Canada that narcotic forms of the hemp plant are distinct and distinguishable from fiber and oilseed forms. In March 1998, new regulations (under the Controlled Drugs and Substances Act) were provided to allow the commercial development of a hemp industry in Canada, and since then more than a thousand licenses have been issued. Hectares licensed for cultivation for 1998–2001 were respectively, 2,500, 14,200, 5,487, and 1,355, the decreasing trend due to a glut of seed produced in 1999 and pessimism over new potential regulations barring exports to the US. Information on the commercial potential of hemp in Canada is in Blade (1998), Marcus (1998), and Pinfold Consulting (1998). In the US, a substantial trade in hemp products has developed, based on imports of hemp fiber, grain, and oil. The American agricultural community has observed this, and has had success at the state level in persuading legislators of the advisability of experimental hemp cultivation as a means of evaluating the wisdom of re-establishing American hemp production. However, because of opposition by the federal government, to date there has only been a small experimental plot in Hawaii. Information on the commercial potential of hemp in the US is presented in the following.
The Spaniards brought hemp to the Americas and cultivated it in Chile starting about 1545. Similar attempts were made in Peru, Colombia, and Mexico, but only in Chile did the crop find success. In July 1605, Samuel Champlain reported the use of grass and hemp clothing by the (Wampanoag) people of Cape Cod and the (Nauset) people of Plymouth Bay told him they harvested hemp in their region where it grew wild to a height of 4 to 5 ft.  In May 1607, "hempe" was among the crops Gabriel Archer observed being cultivated by the natives at the main Powhatan village, where Richmond, Virginia is now situated; and in 1613, Samuell Argall reported wild hemp "better than that in England" growing along the shores of the upper Potomac. As early as 1619, the first Virginia House of Burgesses passed an Act requiring all planters in Virginia to sow "both English and Indian" hemp on their plantations. The Puritans are first known to have cultivated hemp in New England in 1645.
Under federal law, cannabis (from which both CBD and marijuana are derived) is illegal everywhere, although the laws against it aren’t generally enforced in states that have legalized marijuana. Some manufacturers claim that CBD culled from legally imported industrial hemp, which has little to no THC, is fine to ship across the U.S., but many experts disagree, noting that because hemp comes from the same species as marijuana, cannabis sativa, all CBD falls under the DEA’s Schedule 1 designation. “This creative interpretation of the law runs afoul of reality,” says the Brookings Institution, a Washington, DC, think tank.
That leaves those touting CBD’s effectiveness pointing primarily to research in mice and petri dishes. There, CBD (sometimes combined with small amounts of THC) has shown promise for helping pain, neurological conditions like anxiety and PTSD, and the immune system—and therefore potentially arthritis, diabetes, multiple sclerosis, cancer, and more.
Reference citations in some PDQ cancer information summaries may include links to external websites that are operated by individuals or organizations for the purpose of marketing or advocating the use of specific treatments or products. These reference citations are included for informational purposes only. Their inclusion should not be viewed as an endorsement of the content of the websites, or of any treatment or product, by the PDQ Integrative, Alternative, and Complementary Therapies Editorial Board or the National Cancer Institute.
Users have reported toxic symptoms, extreme reactions and serious psychological problems from using synthetic cannabis. These include: high blood, pressure, abdominal pain, nausea and vomiting, chest pain, heart palpitations, severe anxiety and paranoia, fear of dying, hallucinations, tremors and seizures, violent behaviour, and suicidal thoughts. These toxic symptoms have lasting several days and others have experienced long term mental health issues. Tolerance can develop quickly which means you will need more to get the same effect.
Recreational cannabis use centers around one chemical: the psychoactive cannabinoid tetrahydrocannabinol (THC). Consuming this chemical induces euphoric and stimulating sensations commonly referred to as a “high.” For most marijuana users, these sensations are pleasurable and enjoyable. For some, however, THC can induce feelings of anxiety and paranoia, especially in large doses.
It’s easy to see why vaping has become such a popular method for consuming marijuana. The method is remarkably discrete and produces none of the telltale “weed smells” that often betray cannabis users. Vape pens and other hand-held devices are portable and convenient. They’re free of many of the harsh marijuana plant compounds that can harm your lung health, like tars. And companies are getting better at crafting high-quality, flavorful vape cartridges with a wide array of cannabinoid profiles.
Researchers in New Zealand have studied whether cannabis can be used to treat severe motor and vocal tics in those suffering from Tourette syndrome. The study concluded that subjects who took a controlled THC-CBD medicated spray showed marked improvement in the frequency and severity of motor and vocal tics post-treatment. Although the study is only a small clinical trial, it is one of the first to specifically analyze the effects of cannabis on Tourette syndrome.
A chief argument that has been advanced in favor of developing hemp as a paper and pulp source has been that as a non-wood or tree-free fiber source, it can reduce harvesting of primary forests and the threat to associated biodiversity. It has been claimed that hemp produces three to four times as much useable fiber per hectare per annum as forests. However, Wong (1998) notes evidence that in the southern US hemp would produce only twice as much pulp as does a pine plantation (but see discussion below on suitability of hemp as a potential lumber substitute in areas lacking trees).
Hemp seeds contain virtually no THC, but THC contamination results from contact of the seeds with the resin secreted by the epidermal glands on the leaves and floral parts, and also by the failure to sift away all of the bracts (which have the highest concentration of THC of any parts of the plant) that cover the seeds. This results in small levels of THC appearing in hempseed oil and foods made with the seeds. Although most of the western hemp-growing world uses 0.3% THC as a maximum concentration for authorized cultivation of hemp plants, regulations in various countries allow only a much lower level of THC in human food products manufactured from the seeds. Currently, up to 10 ppm THC is permitted in seeds and oil products used for food purposes in Canada. In Germany, more stringent limits were set for food in 2000: 5 ppm in food oil, 0.005 ppm in beverages, and 0.15 ppm in all other foods. The US Drug Enforcement Administration published new regulations on hemp in the Federal Register on October 9th 2001 that in effect 4 months later would ban the food use of hemp in the US because any amount of THC would be unacceptable in foods (follow links at www.hempreport.com/). These proposals are currently being challenged by the hemp industry. Limits have been set because of concerns about possible toxicity and interference with drug tests (Grotenhermen et al. 1998). An extensive analysis of literature dealing with the toxicity of hemp is in Orr and Starodub (1999; see Geiwitz 2001 for an analysis). Because hemp food products are considered to have great economic potential, there is considerable pressure on the hemp industry in North America to reduce THC levels.
American industrialists led by newspaper mogul William Randolph Hearst (who owned vast timberlands) and DuPont executives, who’d begun processing petroleum and wood for plastics, became disgruntled by the way hemp cut into their market shares. A 1994 Vegetarian Times article2 describes the group’s devastatingly successful tactics for twisting the public’s perception of hemp:
The downsides of graphene are its dwindling sources and costly process to mine and import from rural areas in China and India. Hemp, however, can be grown in almost any terrain or country, and produces hemp bast, the key material used to replace graphene, as a waste byproduct of hemp processing. According to Mitlin’s research, hemp processing is 1,000 times cheaper than graphene processing.
Jump up ^ Juliet Eilperin (February 11, 2013), "'Good seed' versus 'evil weed': Hemp activists eye legalization", The Washington Post – via The Japan Times Online, [A] couple of factors — the high taxes the federal government imposed on growing hemp in the late 1930s and again in the early '50s, and then the DEA's interpretation of the 1970 law — made producing hemp nearly impossible. Since the DEA only grants permits in rare instances and demands costly, elaborate security precautions, large-scale hemp growing in the United States is not viable.
The objectivity of scientific evaluation of the medicinal value of marijuana to date has been questioned. In the words of Hirst et al. (1998): “The ...status of cannabis has made modern clinical research almost impossible. This is primarily because of the legal, ethical and bureaucratic difficulties in conducting trials with patients. Additionally, the general attitude towards cannabis, in which it is seen only as a drug of abuse and addiction, has not helped.” In a recent editorial, the respected journal Nature (2001) stated: “Governments, including the US federal government, have until recently refused to sanction the medical use of marijuana, and have also done what they can to prevent its clinical testing. They have defended their inaction by claiming that either step would signal to the public a softening of the so-called ‘war on drugs.’... The pharmacology of cannabinoids is a valid field of scientific investigation. Pharmacologists have the tools and the methodologies to realize its considerable potential, provided the political climate permits them to do so.” Given these current demands for research on medicinal marijuana, it will be necessary to produce crops of drug types of C. sativa.
Spring Hope, NC, Nov. 13, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Hemp, Inc. (OTC PINK: HEMP), a global leader in the industrial hemp industry with bi-coastal processing centers including the largest multipurpose industrial hemp processing facility in the western hemisphere (in Spring Hope, North Carolina), announced today that the company is one of the largest sponsors for the 4th Annual Jack Herer Cup on November 15, 2018. At the event, Hemp, Inc. CEO Bruce Perlowin will receive an award for being a trailblazer in the hemp industry. To learn more about the 4th Annual Jack Herer Cup or to RSVP, click here.
As detailed below, the development of hemp as a new legal crop in North America must be considered in relation to illicit cultivation, so it is important to appreciate the scope of the drug situation. Up until the first half of the 20th century, drug preparations of Cannabis were used predominantly as a recreational inebriant in poor countries and the lower socio-economic classes of developed nations. After World War II, marijuana became associated with the rise of a hedonistic, psychedelic ethos, first in the United States and eventually over much of the world, with the consequent development of a huge international illicit market that exceeds the value of the hemp market during its heyday. Table 3 shows the “economic significance” (dollars generated in the black market plus dollar cost of control measures) of the illicit drug industry associated with C. sativa, and contrasts this with the estimated dollar value of major categories of legitimate uses. In the Netherlands, the annual value of narcotic hemp cultivation (ca. $10 billion) exceeds the value of tulips (Collins 1999). Marijuana has become the most widely disseminated illicit species in the world (Schultes and Hofmann 1980). With the exception of alcohol, it is the most widely used recreational euphoric drug. About 25% of North Americans are believed to have used Cannabis illegally. According to the US National Institute on Drug Abuse (www.nida.nih.gov/Infofax/marijuana.html), more than 72 million Americans (33%) 12 years of age and older have tried marijuana. Cultivation, commerce, and consumption of drug preparations of Cannabis have been proscribed in most countries during the present century. The cost of enforcing the laws against Cannabis in North America is in the billions of dollars annually. In addition, there are substantial social costs, such as adverse effects on users, particularly those who are convicted. Tragically this includes some legitimate farmers who, faced with financial ruin because of the unprofitability of crops being grown, converted to growing marijuana.
In the mid 1990s, the EU provided subsidization for hemp cultivation of ca. $1,050/ha. This support was instrumental in developing a hemp industry in western Europe. However, no comparable support is available in North America, and indeed those contemplating entering into hemp cultivation are faced with extraordinary costs and/or requirements in connection with licensing, security, THC analysis, and record keeping. Those involved in value-added processing and distribution are also faced with legal uncertainties and the regular threat of idiosyncratic, indeed irrational actions of various governments. Simply displaying a C. sativa leaf on advertising has led to the threat of criminal charges in the last decade in several G8 countries. Attempting to export or import hemp products among countries is presently a most uncertain activity.